Sun Pharmaceutical Industries
BSE: 524715 | NSE: SUNPHARMA | ISIN: INE044A01036 | SECTOR: Biotechnology & DrugsOpen
1,040.10High
1,050.10Low
1,034.15Prev Close
1,039.95P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
-Volume
47.23KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
-Ask
-
Company Description
- Biotechnology & Drugs
BSE
524715NSE
SUNPHARMAISIN
INE044A01036
Sun Pharmaceutical Industries Limited is a specialty generic pharmaceutical company. The Company is engaged in the business of manufacturing, developing and marketing a range of generic formulations. It produces a portfolio of generic and specialty medicines targeting a spectrum of chronic and acute treatments. The Company’s product portfolio includes generics, branded generics, specialty, over the counter (OTC)/consumer healthcare products, anti-retrovirals (ARVs), active pharmaceutical ingredients (APIs) and intermediates. Its OTC brands includes Faringosept , Revital, and Volini. The Company offers its products in variety of dosage forms, such as tablets, capsules, sprays, injectables, inhalers, ointments, creams and liquids. Its portfolio of specialty products, branded generics are available across 100 countries. The Company operates manufacturing sites across 6 continents.
Company Officers
C. S. Muralidharan
Chief Financial OfficerUday Baldota
Chief Executive Officer - Taro Pharmaceutical Industries LimitedAbhay Gandhi
Chief Executive Officer - North AmericaKirti Ganorkar
Chief Executive Officer - India BusinessJila Breeze
Executive Vice President, Global Head - QualityAalok Shanghvi
Executive Vice President, Head - Emerging Markets, Head - Global Generics, Research and Development, Business DevelopmentDavinder Singh
Executive Vice President - Sun Global OperationsAnil Rao
Senior Vice President, Chief Information OfficerSapna Purohit
Senior Vice President, Head of Human ResourcesAzadar Khan
Senior Vice President - Corporate Relations and Corporate Social Responsibility, India Regulatory Affairs